CLINICAL TRIALS PROFILE FOR PARATHYROID HORMONE
✉ Email this page to a colleague
All Clinical Trials for parathyroid hormone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000400 ↗ | Alendronate and/or Parathyroid Hormone for Osteoporosis | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 1999-08-01 | This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies. |
NCT00000400 ↗ | Alendronate and/or Parathyroid Hormone for Osteoporosis | Completed | Massachusetts General Hospital | Phase 2 | 1999-08-01 | This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies. |
NCT00000427 ↗ | Effects of Parathyroid Hormone in Men With Osteoporosis | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 3 | 1999-09-01 | Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half year period. |
NCT00000427 ↗ | Effects of Parathyroid Hormone in Men With Osteoporosis | Completed | Massachusetts General Hospital | Phase 3 | 1999-09-01 | Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half year period. |
NCT00000543 ↗ | Oral Calcium in Pregnant Women With Hypertension | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1993-08-01 | To determine of providing calcium supplementation to women with pre-existing hypertension reduces the level of blood pressure, requirement for antihypertensive drugs, and incidence of pre-eclampsia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for parathyroid hormone
Condition Name
Clinical Trial Locations for parathyroid hormone
Trials by Country
Clinical Trial Progress for parathyroid hormone
Clinical Trial Phase
Clinical Trial Sponsors for parathyroid hormone
Sponsor Name